#USA #Exton #Chief Financial Officer #Robert McMahon #West Pharm

West Pharmaceutical Services Welcomes Robert McMahon as New CFO

West Pharmaceutical Services, Inc., a leader in innovative injectable drug administration solutions, is thrilled to announce Robert McMahon as its incoming Chief Financial Officer. The transition will become effective on August 4, 2025. McMahon takes over from Bernard Birkett, who is retiring after a distinguished career with the company. Birkett will continue to support West as a Senior Advisor to the CEO until the end of the year, providing invaluable assistance during this transition.

A Seasoned Leader

Robert McMahon is no stranger to the pharmaceutical and healthcare sectors. With 34 years of experience under his belt, he has served as CFO for several prominent organizations and has successfully navigated the complexities of financial transformations. His impressive track record speaks volumes—establishing effective financial strategies and fostering inspirational leadership. This expertise is expected to play a crucial role as West Pharmaceutical embarks on its next chapter.

Eric M. Green, the President and CEO of West, expressed his enthusiasm about McMahon's appointment, stating, “Bob is an accomplished CFO and business executive within the healthcare industry who has guided several companies through dynamic environments and meaningful financial transformation.” Green emphasized confidence in McMahon's abilities to drive the company’s growth trajectory and enhance shareholder value.

Experience at Agilent Technologies

Before coming to West, McMahon was the Chief Financial Officer at Agilent Technologies Inc. since 2018, overseeing a range of critical financial functions, including finance, audit, treasury, tax, investor relations, IT, and procurement. His efforts at Agilent contributed to solid financial performance during a time of rapid advancements in science and technology.

McMahon's diverse background also includes tenure as CFO at Hologic, Inc., and prolonged experience in various executive financial roles at Johnson & Johnson for over two decades. He has been recognized for his ability to offer finance-related insights, enabling companies to make informed strategic decisions.

Vision for West’s Future

Expressing his excitement for this new opportunity, McMahon remarked, “I’m thrilled to join such a well-positioned company with a talented team dedicated to enhancing patient health.” He acknowledges West's rich history of innovation that spans more than one hundred years and aims to collaborate with the leadership team to contribute to the company's future direction.

West Pharmaceutical Services is known for its commitment to safe and effective drug containment and delivery, producing more than 41 billion components and devices annually. With over 10,000 team members at 50 facilities globally, West has achieved remarkable milestones, generating $2.89 billion in net sales during the fiscal year 2024.

Conclusion

As Robert McMahon steps into his new role, he brings forth a wealth of experience and a vision for sustained growth at West Pharmaceutical Services. With an emphasis on patient health, operational excellence, and financial strategy, McMahon is expected to steer West into a promising future while continuing the legacy left by his predecessor, Bernard Birkett. Investors and stakeholders alike can anticipate exciting developments from this dynamic leader in the medical pharmaceutical sector.